GERMANY – Bayer and Mammoth Biosciences have announced an agreement to use the latter’s CRISPR systems to develop in vivo gene-editing therapies, with an initial focus on liver-targeted diseases. Bayer…
Read MoreBayer in gene editing tech deal with Mammoth Biosciences
